Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating the Efficacy of Controlled Pulsatile Intravenous Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease- A Pilot Study.

Next Previous
Trial Profile

Evaluating the Efficacy of Controlled Pulsatile Intravenous Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease- A Pilot Study.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use

Most Recent Events

  • 12 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 24 Apr 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
  • 24 Apr 2013 Official title amended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top